Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?

Table 5 Clinical studies of second-line targeted therapies

Ref.	Regimen	Sample size	RR1	PFS/TTP (mo)	Med OS (mo)	1 yr survival
Ignatiadis et al[97], 2006	Gefitinib, docetaxel	26	0%	2.1	2.9	NR
Brell et al[98], 2009	Gefitinib, docetaxel	41	2.4%	1.8	4.5	0%
Kulke et al[55], 2007	Erlotinib, capecitabine	30	10%	3.4	6.5	26%
Tang et al[54], 2009	Erlotinib	50	0%	1.6	4.1	6 m = 39%3
Iyer et al[99], 2010	Erlotinib	18	0%	1.4	3.1	NR
Bodoky et al[59], 2012	Selumetinib	32	6.3%	2.1	5.4	NR
Ko et al[61], 2013	Selumetinib, erlotinib	46	0%	2.6	7.5	NR
Wolpin et al[62], 2009	Everolimus	33	0%	1.8	4.5	NR
Garrido-Laguna et al[63], 2010	Sirolimus	31	0%	NR	NR	6 m = 26%3
Javle et al[64], 2010	Everolimus, erlotinib	16	0%	1.6	2.9	NR
Javle et al[64], 2010	Temsirolimus	5	0%	0.6	1.5	NR
Dragovich et al[68], 2008	Vatalinib	65	NR%	6 m = 14%3	6 m = 31%3	NR
O’Reilly et al[69], 2010	Sunitinib	77	1.4%	1.3	3.7	NR
Ko et al[67], 2010	Bevacizumab, erlotinib	36	2.8%	1.3	3.4	6 m = 22%3
Astsaturov et al[100], 2011	Bevacizumab	16	0%	1.4	5.5	NR
Astsaturov et al[100], 2011	Bevacizumab, docetaxel	16	0%	1.6	4.2	NR
Milella et al[73], 2004	Celecoxib, 5-FU	17	12%	1.9	3.5	NR
Pino et al[74], 2009	Celecoxib, capecitabine2	35	8.6%	4.0	4.4	NR
Starling et al[101], 2012	Imatinib, gem, oxaliplatin	27	7.4%	4.6	5.6	28%
Carvajal et al[102], 2009	Flavopiridol, docetaxel	10	0%	1.9	4.2	0%
Nallapareddy et al[103], 2010	Sarcatinib	19	0%	1.6	2.5	NR

¹Intent-to-treat analysis;

²Pooled analysis of pancreatic (86%) and biliary (14%) cancer;

³6 m: 6 mo survival rate. 5-FU: 5-Fluorouracil; Gem: Gemcitabine; NR: Not reported; PFS: Progression free survival; OS: Overall survival; TTP: Time to progression.